Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | MC3R | P41968 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetophenone SCHEMBL28325530 | 0.85 | KDM4E (0.53) | KDM4EMAPTTDP1NAPRTHCAR2 | |
| SCHEMBL9946197 | 0.84 | KDM4E (0.53) | KDM4EMAPTTDP1NAPRTHCAR2 | |
| SCHEMBL8509785 | 0.80 | KDM4E (0.53) | KDM4EMAPTTDP1NAPRTHCAR2 | |
| SCHEMBL6603504 | 0.80 | KDM4E (0.53) | KDM4EMAPTTDP1NAPRTHCAR2 | |
| SCHEMBL9782940 | 0.80 | KMT2A (0.38) | KDM4EMAPTTDP1TSHRPOLB | |
| SCHEMBL28801662 | 0.80 | KDM4E (0.59) | KDM4EMAPTTDP1NAPRTHCAR2 | |
| SCHEMBL14684073 | 0.79 | KDM4E (0.57) | KDM4EMAPTTDP1NAPRTHCAR2 | |
| SCHEMBL6610574 | 0.79 | KDM4E (0.57) | KDM4ENAPRTHCAR2TSHRADORA3 | |
| SCHEMBL13116469 | 0.79 | TSHR (0.61) | KDM4EMAPTTDP1NAPRTHCAR2 | |
| SCHEMBL17540749 | 0.79 | KDM4E (0.57) | KDM4EMAPTTDP1NAPRTHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | claimed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | claimed |
| CN-101494999-A | Method for using organic compound | GIVAUDAN SA (CH) | 2009-07-29 | — | — | CN | claimed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | claimed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | claimed |
| EP-3183250-B1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | CLAP CO LTD (KR) | 2023-10-04 | — | — | EP | disclosed |
| CN-113717114-B | 2-acetylpyrazine continuous recrystallization device, method and application thereof | 济南悟通生物科技有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| EP-3183757-B1 | ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM | CLAP CO LTD (KR) | 2022-05-04 | — | — | EP | disclosed |
| CN-113717114-A | 2-acetylpyrazine continuous recrystallization device, method and application thereof | 济南悟通生物科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
| EP-0256839-B1 | SMOKING COMPOSITIONS CONTAINING A FLAVORANT ADDITIVE | Philip Morris Products Inc. (US) | 1991-11-06 | — | — | EP | disclosed |
| US-5017235-A | Smoking compositions containing a 2,5-diacylpyrazine flavorant additive | PHILIP MORRIS INC. (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0256839-A1 | Smoking compositions containing a flavorant additive | Philip Morris Products Inc. (US) | 1988-02-24 | — | — | EP | disclosed |
| US-4588813-A | 1-pyrazinyl-1-propanone derivatives useful as flavorants in smoking compositions | PHILIP MORRIS INCORPORATED (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0076085-A1 | Production of monoacylpyrazines | PHILIP MORRIS INCORPORATED (US) | 1983-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311403-A1 | Method of Using Organic Compounds | MGLL, GK, LIPC | KDM4E 3200/4885MAPT 2208/4885TDP1 3828/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | KDM4E 2971/4885MAPT 3133/4885TDP1 4025/4885 |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | RXFP3, AVPR2, RXFP1 | KDM4E 3851/4885MAPT 9/4885TDP1 433/4885 |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | IDE, SI, GPR119 | KDM4E 2236/4885MAPT 236/4885TDP1 2022/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | KDM4E 3646/4885MAPT 150/4885TDP1 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.